中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

二维剪切波弹性成像和血清学模型在慢性乙型肝炎患者肝纤维化分期中的应用价值

黄玉洁 冯斯奕

引用本文:
Citation:

二维剪切波弹性成像和血清学模型在慢性乙型肝炎患者肝纤维化分期中的应用价值

DOI: 10.12449/JCH240312
基金项目: 

福建省自然科学基金 (2022J011285)

伦理学声明:本研究方案于2022年3月1日经由福建医科大学孟超肝胆医院伦理委员会审批,批号:科审2022-028-01,所纳入患者均签署知情同意书。
利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:黄玉洁负责课题设计,资料分析,撰写论文;冯斯奕指导撰写文章并最后定稿。
详细信息
    通信作者:

    冯斯奕, 75677207@qq.com (ORCID: 0000-0001-6305-0337)

Application value of two-dimensional shear wave elastography and serological models in the staging of liver fibrosis in patients with chronic hepatitis B

Research funding: 

Fujian Natural Science Foundation (2022J011285)

More Information
    Corresponding author: FENG Siyi, 75677207@qq.com (ORCID: 0000-0001-6305-0337)
  • 摘要:   目的  探讨二维剪切波弹性成像和血清学模型及其联合应用在慢性乙型肝炎患者肝纤维化分期中的诊断价值。  方法  回顾性分析2020年8月—2022年8月在福建医科大学孟超肝胆医院进行过二维剪切波弹性成像(2D-SWE)与肝组织病理学检查的327例慢性乙型肝炎患者的临床资料,提取患者的性别、年龄、血清学指标和2D-SWE结果,根据肝纤维化程度分为S0~S1组、S≥2组、S≥3组和S=4组,根据血清学指标计算血清学模型。采用Spearman相关分析法对2D-SWE和血清学模型与肝纤维化分期进行相关分析,以肝组织病理结果为标准,绘制受试者工作特征曲线,比较各参数及其联合应用诊断肝纤维化分期的效能,并采用Delong检验比较不同方法间的差异。  结果  2D-SWE检测LSM值与肝纤维化分期呈强相关性(r=0.741,P<0.001),血清学模型中除了AAR外的其他6种(APRI、FIB-4、GPR、GP、RPR、S指数)与肝纤维化分期均存在正相关(P值均<0.001)。2D-SWE诊断S≥2、S≥3和S=4肝纤维化的AUC值分别为0.878、0.932、0.942,显著高于血清学模型(P值均<0.001),其最佳截断值分别为6.9 kPa、7.9 kPa、9.4 kPa。血清学模型中APRI在诊断S≥2、S=4的AUC值最高(0.788、0.875),S指数在诊断S≥3的AUC值最高(0.846)。在诊断S≥2、S≥3、S=4时2D-SWE和APRI联合能将AUC值分别提高到0.887、0.938、0.950,诊断S≥2、S≥3、S=4时2D-SWE和S指数联合诊断的AUC值分别为0.879、0.935、0.941;但单独使用2D-SWE与上述联合诊断并无统计学差异(P值均>0.05)。  结论  2D-SWE对肝纤维化分期的诊断效能显著优于7种血清学模型;血清学模型具有一定的诊断价值,其中APRI、S指数的价值较高;单独使用2D-SWE与指标联合并无明显差异,联合并不能显著提高诊断效能,新的联合诊断方法仍有待探索。

     

  • 图  1  2D-SWE肝硬度检测图示

    Figure  1.  2D-SWE liver stiffness test diagram

    图  2  2D-SWE和血清学模型单独诊断肝纤维化的ROC曲线

    注: a,S≥2期;b,S≥3期;c,S=4期。

    Figure  2.  ROC curves of 2D-SWE and serological models for the diagnosis of liver fibrosis

    图  3  2D-SWE联合APRI诊断肝纤维化的ROC曲线

    注: a,S≥2期;b,S≥3期;c,S=4期。

    Figure  3.  ROC curve of 2D-SWE combined with APRI in diagnosis of liver fibrosis

    图  4  2D-SWE联合S指数诊断肝纤维化的ROC曲线

    注: a,S≥2期;b,S≥3期;c,S=4期。

    Figure  4.  ROC curve of 2D-SWE combined with S index in diagnosis of liver fibrosis

    表  1  患者基础情况

    Table  1.   Patient basic information table

    项目 数值
    性别(男/女,例) 199/128
    年龄(岁) 37(31~46)
    LSM(kPa) 5.8(4.4~8.0)
    ALT(IU/L) 35(22~51)
    AST(IU/L) 28(22~39)
    GGT(U/L) 26(16~53)
    Alb(g/L) 43(40~45)
    Glo(g/L) 30(27~33)
    PLT(×109/L) 215(180~255)
    RDW 12.8(12.4~13.3)
    APRI 0.34(0.24~0.53)
    FIB-4 0.85(0.63~1.34)
    AAR 0.88(0.68~1.12)
    GPR 0.12(0.07~0.31)
    GP 13.73(11.81~17.26)
    PRP 0.06(0.05~0.07)
    S指数 0.07(0.04~0.18)
    肝纤维化分期[例(%)]
    S0~1 195(59.6)
    S2 67(20.5)
    S3 33(10.1)
    S4 32(9.8)
    下载: 导出CSV

    表  2  2D-SWE、各血清学模型与肝纤维化分期的相关性

    Table  2.   Correlation between 2D-SWE、serological models and hepatic fibrosis stage

    项目 r P
    LSM 0.741 <0.001
    APRI 0.498 <0.001
    FIB-4 0.493 <0.001
    GPR 0.348 <0.001
    GP 0.509 <0.001
    RPR 0.285 <0.001
    S指数 0.329 <0.001
    AAR 0.012 0.835
    下载: 导出CSV

    表  3  2D-SWE和各血清学模型单独诊断肝纤维化S≥2的效能比较

    Table  3.   Comparison of the efficacy of 2D-SWE and each serological model in the diagnosis of liver fibrosis S≥2

    项目 最佳截断值 AUC 95%CI 敏感度(%) 特异度(%)
    2D-SWE 6.90 kPa 0.878 0.838~0.919 71.2 92.3
    APRI 0.32 0.788 0.738~0.839 81.1 66.7
    FIB-4 0.96 0.710 0.650~0.769 61.4 75.9
    AAR 0.83 0.454 0.391~0.517 54.5 58.5
    GPR 0.10 0.778 0.727~0.828 84.1 61.0
    GP 15.4 0.735 0.677~0.792 61.4 79.0
    PRP 0.07 0.694 0.635~0.753 40.9 88.2
    S指数 0.08 0.776 0.725~0.826 66.7 76.4
    下载: 导出CSV

    表  4  2D-SWE和各血清学模型单独诊断肝纤维化S≥3的效能比较

    Table  4.   Comparison of the efficacy of 2D-SWE and each serological model in the diagnosis of liver fibrosis S≥3

    项目 最佳截断值 AUC 95%CI 敏感度(%) 特异度(%)
    2D-SWE 7.90 kPa 0.932 0.896~0.968 86.2 90.5
    APRI 0.42 0.825 0.765~0.885 78.5 75.2
    FIB-4 1.13 0.801 0.737~0.866 70.8 77.5
    AAR 1.63 0.516 0.436~0.596 12.3 96.6
    GPR 0.16 0.841 0.793~0.890 83.1 72.5
    GP 15.63 0.777 0.703~0.852 72.3 76.7
    PRP 0.07 0.749 0.678~0.821 53.8 84.0
    S指数 0.12 0.846 0.799~0.894 75.4 80.9
    下载: 导出CSV

    表  5  2D-SWE和各血清学模型单独诊断肝纤维化S=4的效能比较

    Table  5.   Comparison of the efficacy of 2D-SWE and each serological model in the diagnosis of liver fibrosis S=4

    项目 最佳截断值 AUC 95%CI 敏感度(%) 特异度(%)
    2D-SWE 9.40 kPa 0.942 0.902~0.982 84.4 93.6
    APRI 0.44 0.875 0.820~0.929 90.6 74.6
    FIB-4 1.13 0.864 0.792~0.936 87.5 73.9
    AAR 1.73 0.550 0.444~0.656 15.6 99.3
    GPR 0.22 0.837 0.782~0.891 81.2 74.6
    GP 15.79 0.885 0.819~0.952 90.6 74.9
    PRP 0.09 0.844 0.767~0.920 78.1 82.4
    S指数 0.12 0.835 0.779~0.891 81.2 75.3
    下载: 导出CSV

    表  6  2D-SWE联合血清学模型诊断肝纤维化的效能比较

    Table  6.   Comparison of efficacy of 2D-SWE combined serological model in the diagnosis of liver fibrosis

    项目 肝纤维化分期 AUC 95%CI
    2D-SWE联合APRI S≥2 0.887 0.847~0.927
    S≥3 0.938 0.904~0.972
    S=4 0.950 0.915~0.985
    2D-SWE联合S指数 S≥2 0.879 0.838~0.919
    S≥3 0.935 0.900~0.971
    S=4 0.941 0.902~0.980
    下载: 导出CSV
  • [1] SEKIBA K, OTSUKA M, OHNO M, et al. Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA[J]. World J Gastroenterol, 2018, 24( 21): 2261- 2268. DOI: 10.3748/wjg.v24.i21.2261.
    [2] ROEHLEN N, CROUCHET E, BAUMERT TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives[J]. Cells, 2020, 9( 4). DOI: 10.3390/cells9040875.
    [3] LI YP, LI CY, CAO D, et al. New progress in non-invasive diagnostic models of chronic hepatitis B liver fibrosis[J]. Chin Hepatol, 2017, 22( 12): 1144- 1146. DOI: 10.14000/j.cnki.issn.1008-1704.2017.12.023.

    李艳平, 李春艳, 曹丹, 等. 慢性乙型肝炎肝纤维化无创诊断模型研究新进展[J]. 肝脏, 2017, 22( 12): 1144- 1146. DOI: 10.14000/j.cnki.issn.1008-1704.2017.12.023.
    [4] WANG K, LU X, ZHOU H, et al. Deep learning radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study[J]. Gut, 2019, 68( 4): 729- 741. DOI: 10.1136/gutjnl-2018-316204.
    [5] HERRMANN E, de LÉDINGHEN V, CASSINOTTO C, et al. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis[J]. Hepatology, 2018, 67( 1): 260- 272. DOI: 10.1002/hep.29179.
    [6] Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [7] SONNEVELD MJ, BROUWER WP, CHAN HL, et al. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study[J]. Lancet Gastroenterol Hepatol, 2019, 4( 7): 538- 544. DOI: 10.1016/S2468-1253(19)30087-1.
    [8] XU XL, JIANG LS, WU CS, et al. The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool?[J]. J Formos Med Assoc, 2022, 121( 2): 454- 466. DOI: 10.1016/j.jfma.2021.07.013.
    [9] ZHOU L, WANG SB, CHEN SG, et al. Prognostic value of ALT, AST, and AAR in hepatocellular carcinoma with B-type hepatitis-associated cirrhosis after radical hepatectomy[J]. Clin Lab, 2018, 64( 10): 1739- 1747. DOI: 10.7754/Clin.Lab.2018.180532.
    [10] DING R, LU W, ZHOU X, et al. A novel non-invasive model based on GPR for the prediction of liver fibrosis in patients with chronic hepatitis B[J]. Front Med(Lausanne), 2021, 8: 727706. DOI: 10.3389/fmed.2021.727706.
    [11] LI Q, LU C, LI W, et al. Globulin-platelet model predicts significant fibrosis and cirrhosis in CHB patients with high HBV DNA and mildly elevated alanine transaminase levels[J]. Clin Exp Med, 2018, 18( 1): 71- 78. DOI: 10.1007/s10238-017-0472-3.
    [12] YUYUN D, ZHIHUA T, HAIJUN W, et al. Predictive value of the red blood cell distribution width-to-platelet ratio for hepatic fibrosis[J]. Scand J Gastroenterol, 2019, 54( 1): 81- 86. DOI: 10.1080/00365521.2018.1558786.
    [13] TAG-ADEEN M, OMAR MZ, ABD-ELSALAM FM, et al. Assessment of liver fibrosis in Egyptian chronic hepatitis B patients: A comparative study including 5 noninvasive indexes[J]. Medicine(Baltimore), 2018, 97( 6): e9781. DOI: 10.1097/MD.0000000000009781.
    [14] Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35( 10): 2163- 2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35( 10): 2163- 2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
    [15] DESMET VJ, GERBER M, HOOFNAGLE JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging[J]. Hepatology, 1994, 19( 6): 1513- 1520.
    [16] DONG M, WU J, YU X, et al. Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients[J]. Liver Int, 2018, 38( 9): 1562- 1570. DOI: 10.1111/liv.13688.
    [17] TAO ZZ, WANG YL, SUN YH, et al. Comparison of different Young’s modulus determination by two-dimensional shear wave elastography in predicting liver fibrosis in patients with chronic hepatitis B.[J]. J Prac Hepatol, 2023, 26( 3): 328- 331. DOI: 10.3969/j.issn.1672-5069.2023.03.007.

    陶贞贞, 王永莉, 孙红艳, 等. 二维剪切波弹性成像诊断慢性乙型肝炎患者肝纤维化价值研究[J]. 实用肝脏病杂志, 2023, 26( 3): 328- 331. DOI: 10.3969/j.issn.1672-5069.2023.03.007.
    [18] OSMAN AM, SHIMY A EL, AZIZ MM ABD EL. 2D shear wave elastography(SWE) performance versus vibration-controlled transient elastography(VCTE/fibroscan) in the assessment of liver stiffness in chronic hepatitis[J]. Insights Imaging, 2020, 11( 1): 38. DOI: 10.1186/s13244-020-0839-y.
    [19] GUO H, LIAO M, JIN J, et al. How intrahepatic cholestasis affects liver stiffness in patients with chronic hepatitis B: a study of 1197 patients with liver biopsy[J]. Eur Radiol, 2020, 30( 2): 1096- 1104. DOI: 10.1007/s00330-019-06451-x.
    [20] EKIN N, UCMAK F, EBIK B, et al. GPR, King’s Score and S-Index are superior to other non-invasive fibrosis markers in predicting the liver fibrosis in chronic hepatitis B patients[J]. Acta Gastroenterol Belg, 2022, 85( 1): 62- 68. DOI: 10.51821/85.1.9156.
    [21] KAVAK S, KAYA S, SENOL A, et al. Evaluation of liver fibrosis in chronic hepatitis B patients with 2D shear wave elastography with propagation map guidance: a single-centre study[J]. BMC Med Imaging, 2022, 22( 1): 50. DOI: 10.1186/s12880-022-00777-7.
    [22] ZHUANG Y, DING H, ZHANG Y, et al. Two-dimensional shear-wave elastography performance in the noninvasive evaluation of liver fibrosis in patients with chronic hepatitis B: Comparison with serum fibrosis indexes[J]. Radiology, 2017, 283( 3): 873- 882. DOI: 10.1148/radiol.2016160131.
  • 加载中
图(4) / 表(6)
计量
  • 文章访问数:  87
  • HTML全文浏览量:  42
  • PDF下载量:  27
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-06-21
  • 录用日期:  2023-07-10
  • 出版日期:  2024-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回